A next-generation anesthesia system expanding the use of inhaled anesthetics worldwide.
Clarity-IA® is based on a worldwide exclusively licensed portfolio of 55 patents and applications.
Unique platform technology:
Converts any existing ventilator into the equivalent of a $75,000 anesthesia machine WITH ZERO CAPITAL COSTS to the hospital.
Self-regulation technology adapts in real time to changing conditions, ensuring accuracy of dosing and reducing staff work load.
Disposable component allows the device to isolate airflow between each patient and the ventilator, thereby increasing patient safety by eliminating the risk of inhaling cross-contaminated air.
Platform technology lends itself to deliver an array of inhaled drugs.
Initial Indication: Intended for the delivery and maintenance of inhaled medical gases for patients weighing between 80-330 lbs and requiring inhalation anesthesia and sedation during mechanical ventilation under the care of a trained healthcare professional.
Clarity-IA® addresses the widely recognized link between sedation practices and incidence of delirium in patients requiring life support (i.e. breathing on a ventilator).
Delirium is common with approximately 75% of patients on mechanical ventilation (or life support),* resulting in an estimated $140 billion per year in post-hospital care.**
First Wave’s Clarity-IA® next-gen system breaks this cycle by improving the precision of sedation and anesthesia.
Inhaled sedatives and anesthetics clear faster, reducing tolerance buildup in comparison to IV sedation.
Additional benefits include:
Lowering IV sedation dosing and duration outside approved labels
Reducing risk of delirium and pneumonia
Minimizing the cost and time spent in the ICU
* Girard, et. al., (2018). Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study. The Lancet, 6(3), 213-222. https://doi.org/10.1016/S2213-2600(18)30062-6
** Leslie, DL & Inouye, SK, (2011). The importance of delirium: economic and societal costs. Journal of the American Geriatric Society, 59(S2), S241-3. https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/j.1532-5415.2011.03671.x
Clarity Gas Delivery System
Other Inhaled Drugs